No Data
No Data
CareDx Stock Climbs 16% on Medicare Coverage Update
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Raises Target Price to $40
Express News | CareDx Shares Are Trading Higher After the CMS Retired a Draft Policy That Would Have Restricted Coverage for Non-invasive Blood-based Surveillance Testing for Allograft Rejection
Express News | CareDx Announces CMS Retires Draft Policy Restricting Coverage, Restoring Longstanding Coverage For AlloSure, AlloMap, And HeartCare Through Surveillance Testing For Allograft Rejection
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?